SG11202002258WA - Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness - Google Patents
Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illnessInfo
- Publication number
- SG11202002258WA SG11202002258WA SG11202002258WA SG11202002258WA SG11202002258WA SG 11202002258W A SG11202002258W A SG 11202002258WA SG 11202002258W A SG11202002258W A SG 11202002258WA SG 11202002258W A SG11202002258W A SG 11202002258WA SG 11202002258W A SG11202002258W A SG 11202002258WA
- Authority
- SG
- Singapore
- Prior art keywords
- adrenomedullin
- adm
- illness
- symptoms
- therapy
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17192999 | 2017-09-25 | ||
EP17203370 | 2017-11-23 | ||
PCT/EP2018/075987 WO2019057992A2 (fr) | 2017-09-25 | 2018-09-25 | Liant anti-adrénomédulline (adm) destiné à être utilisé pour traiter ou prévenir les symptômes d'une maladie |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002258WA true SG11202002258WA (en) | 2020-04-29 |
Family
ID=63722372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002258WA SG11202002258WA (en) | 2017-09-25 | 2018-09-25 | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220227854A1 (fr) |
EP (4) | EP4159230A1 (fr) |
JP (1) | JP7461875B2 (fr) |
KR (1) | KR20200088302A (fr) |
CN (1) | CN111511390A (fr) |
AU (2) | AU2018335438A1 (fr) |
BR (1) | BR112020005450A2 (fr) |
CA (1) | CA3076691A1 (fr) |
IL (1) | IL273533A (fr) |
MX (1) | MX2020003538A (fr) |
SG (1) | SG11202002258WA (fr) |
WO (1) | WO2019057992A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114556100A (zh) | 2019-08-30 | 2022-05-27 | 4Teen4制药有限公司 | 用于治疗休克的疗法指引和/或疗法监测 |
EP3871689A1 (fr) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anticorps anti-adm se liant à l'extrémité n-terminale libre pour accélérer la transition de l'adm-gly vers la bio-adm chez les patients dont le rapport adm-gly/bio-adm est supérieur à un seuil et combinaison avec la vitamine c |
US20230104578A1 (en) * | 2020-02-27 | 2023-04-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
CA3112051A1 (fr) * | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedulline ou fragment connexe dans les patients infectes par la maladie a coronavirus et traitements au moyen de liants contre l'adrenomedulline |
CN111893085A (zh) * | 2020-08-04 | 2020-11-06 | 北京臻溪谷医学研究中心(有限合伙) | 一种通过干细胞体外分化获得人工皮肤的方法及其应用 |
WO2024017331A1 (fr) * | 2022-07-20 | 2024-01-25 | 上海济煜医药科技有限公司 | Anticorps anti-adrénomédulin non neutralisant, son procédé de préparation et son utilisation |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1992020791A1 (fr) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methode de production de chainons de paires de liaison specifique |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0746609A4 (fr) | 1991-12-17 | 1997-12-17 | Genpharm Int | Animaux transgeniques non humains capables de produire des anticorps heterologues |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
IL160289A0 (en) | 2001-08-30 | 2004-07-25 | Biorexis Pharmaceutical Corp | Modified transferrin fusion proteins |
EP2298278B1 (fr) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prévention et réduction de perte sanguine et la réponse inflammatoire |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
ATE527353T1 (de) | 2007-12-19 | 2011-10-15 | Affibody Ab | Pdgf-bindendes polypeptid aus protein a |
NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
BR112012004314A2 (pt) | 2009-08-27 | 2016-11-29 | Covagen Ag | compostos de ligação a il-17 e usos medicinais desses compostos |
CA2778871C (fr) | 2009-12-14 | 2017-08-01 | Scil Proteins Gmbh | Proteines d'ubiquitine modifiee possedant une activite de liaison specifique pour l'extradomaine b de la fibronectine |
WO2011154420A2 (fr) | 2010-06-08 | 2011-12-15 | Pieris Ag | Mutéines de lipocaline des larmes se liant à il-4 r alpha |
HUE045940T2 (hu) | 2011-11-16 | 2020-01-28 | Adrenomed Ag | Adrenomedullinhoz kötõdõ anti-adrenomedullin (ADM) antitest vagy anti-ADM antitest fragmens vagy anti-ADM nem-Ig váz egy páciens akut betegségének vagy akut állapotának kezelésében a keringés stabilizálására történõ alkalmazásra |
RU2662671C2 (ru) * | 2011-11-16 | 2018-07-26 | Адреномед Аг | АНТИТЕЛО К АДРЕНОМЕДУЛЛИНУ (ADM) ИЛИ ФРАГМЕНТ АНТИ-ADM АНТИТЕЛА, ИЛИ АНТИ-ADM HE-Ig КАРКАС ДЛЯ ПРИМЕНЕНИЯ В ТЕРАПИИ |
CA2856136A1 (fr) * | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anticorps anti-adrenomedulline (adm) ou fragment d'anticorps anti-adm ou echafaudage non-ig anti-adm pour la reduction du risque de mortalite chez un patient atteint d'une maladiechronique ou aigue ou d'un etat aigu |
EP2780717B1 (fr) * | 2011-11-16 | 2016-12-21 | sphingotec GmbH | Dosages d'adrénomédulline et procédés de détermination de l'adrénomédulline mature |
US10598674B2 (en) * | 2013-03-20 | 2020-03-24 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
WO2017186928A1 (fr) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Arn codant pour un anticorps |
CN110167962B (zh) * | 2016-12-16 | 2024-06-07 | 艾德里诺医药公司 | 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
-
2018
- 2018-09-25 MX MX2020003538A patent/MX2020003538A/es unknown
- 2018-09-25 EP EP22198142.6A patent/EP4159230A1/fr active Pending
- 2018-09-25 KR KR1020207011620A patent/KR20200088302A/ko not_active Application Discontinuation
- 2018-09-25 BR BR112020005450-0A patent/BR112020005450A2/pt unknown
- 2018-09-25 CN CN201880062062.1A patent/CN111511390A/zh active Pending
- 2018-09-25 SG SG11202002258WA patent/SG11202002258WA/en unknown
- 2018-09-25 EP EP22198106.1A patent/EP4159229A1/fr active Pending
- 2018-09-25 EP EP18781997.4A patent/EP3687567A2/fr active Pending
- 2018-09-25 WO PCT/EP2018/075987 patent/WO2019057992A2/fr active Application Filing
- 2018-09-25 JP JP2020517143A patent/JP7461875B2/ja active Active
- 2018-09-25 AU AU2018335438A patent/AU2018335438A1/en active Pending
- 2018-09-25 EP EP21154857.3A patent/EP3854414A1/fr not_active Withdrawn
- 2018-09-25 CA CA3076691A patent/CA3076691A1/fr active Pending
- 2018-09-25 US US16/650,474 patent/US20220227854A1/en active Pending
-
2020
- 2020-03-23 IL IL273533A patent/IL273533A/en unknown
-
2023
- 2023-03-09 AU AU2023201479A patent/AU2023201479A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020005450A2 (pt) | 2020-09-29 |
AU2023201479A1 (en) | 2023-04-13 |
JP2020535151A (ja) | 2020-12-03 |
JP7461875B2 (ja) | 2024-04-04 |
WO2019057992A2 (fr) | 2019-03-28 |
EP3687567A2 (fr) | 2020-08-05 |
EP4159229A1 (fr) | 2023-04-05 |
AU2018335438A1 (en) | 2020-04-09 |
CA3076691A1 (fr) | 2019-03-28 |
RU2020114429A (ru) | 2021-10-27 |
US20220227854A1 (en) | 2022-07-21 |
EP3854414A1 (fr) | 2021-07-28 |
IL273533A (en) | 2020-05-31 |
KR20200088302A (ko) | 2020-07-22 |
EP4159230A1 (fr) | 2023-04-05 |
WO2019057992A3 (fr) | 2019-05-02 |
MX2020003538A (es) | 2020-07-29 |
CN111511390A (zh) | 2020-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273533A (en) | Antiadrenomedullin (ADM) binder for use in treating or preventing symptoms of disease | |
HK1251257A1 (zh) | 用於醫治疾病的外泌體的用途 | |
EP2981274A4 (fr) | Souches probiotiques destinées au traitement ou à la prévention de l'ostéoporose | |
HK1225637A1 (zh) | 功能性消化道障礙預防和/或改善劑 | |
PL3197556T3 (pl) | KOMPOZYCJA DO ZAPOBIEGANIA l/LUB LECZENIA OBJAWÓW ALERGII | |
GB201522329D0 (en) | Use of adjuvants for the prevention and/or treatment of autoimmune diseases | |
HUE045532T2 (hu) | Preventív és/vagy terápiás szer immunbetegségekre | |
IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
PT3548006T (pt) | Composição para utilização no tratamento de alterações intestinais | |
IL252493B (en) | Compounds for use in the prevention or treatment of cancer | |
LT3405197T (lt) | Delgocitinibo panaudojimas lėtinės rankų egzemos gydymui | |
GB201700526D0 (en) | Therapeutic use | |
PT3191112T (pt) | Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura | |
EP3720449C0 (fr) | Composition destinée à être utilisée dans la prévention ou le traitement de la salmonellose | |
IL247616B (en) | Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit | |
SG10201607658RA (en) | Electronic gaming system adapted for simultaneous use of multiple users | |
EP3222281A4 (fr) | Agent prophylactique et thérapeutique contre la maladie c liaque | |
HK1257288A1 (zh) | Pi3k的活性或功能的抑制劑用於治療原發性舍格倫綜合征的用途 | |
EP3297443A4 (fr) | Composition à base d'herbes pour le traitement de douleur du dos |